Benin Management CORP bought a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,000 shares of the biotechnology company’s stock, valued at approximately $207,000.
Several other large investors have also made changes to their positions in the stock. Macquarie Group Ltd. boosted its stake in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares in the last quarter. Invictus RG purchased a new stake in Repligen Corporation during the first quarter valued at $233,000. Karp Capital Management Corp purchased a new stake in Repligen Corporation during the first quarter valued at $506,000. BNP Paribas Arbitrage SA boosted its stake in Repligen Corporation by 13.2% in the first quarter. BNP Paribas Arbitrage SA now owns 6,475 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 753 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Repligen Corporation by 48.9% in the first quarter. Sei Investments Co. now owns 126,600 shares of the biotechnology company’s stock valued at $4,456,000 after buying an additional 41,600 shares in the last quarter. 99.02% of the stock is owned by institutional investors.
Repligen Corporation (RGEN) opened at 41.18 on Friday. The firm’s 50-day moving average price is $41.91 and its 200 day moving average price is $36.63. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The firm has a market cap of $1.54 billion, a P/E ratio of 80.59 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the company posted $0.16 EPS. Equities analysts forecast that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.
RGEN has been the subject of several recent analyst reports. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. First Analysis reaffirmed an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. William Blair started coverage on Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating for the company. Finally, Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $42.00.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.